Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL ) 3.880 +0.020 (+0.52%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vigil Neuroscience, Inc. - Common Stock < Previous 1 2 3 4 5 Next > 12 Health Care Stocks Moving In Wednesday's After-Market Session June 12, 2024 Via Benzinga 3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition June 11, 2024 Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments. Via InvestorPlace 3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition June 11, 2024 Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. Via InvestorPlace Vigil Neuroscience to Present in Upcoming June Investor Conferences May 30, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience: Q4 Earnings Insights March 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session May 08, 2024 Via Benzinga Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference May 08, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024 May 07, 2024 VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update May 07, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting April 17, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023 March 26, 2024 VIGL stock results show that Vigil Neuroscience missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 26, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer March 20, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting March 13, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days March 12, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 March 06, 2024 Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to... From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024 February 29, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference February 07, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session January 08, 2024 Via Benzinga Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones January 03, 2024 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference November 22, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Why Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today? November 17, 2023 Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with adult-onset leukoencephalopathy... Via Benzinga Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session November 17, 2023 Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session November 17, 2023 Via Benzinga US Stocks Edge Lower; Housing Starts Rise In October November 17, 2023 U.S. stocks traded slightly lower this morning, with the Nasdaq Composite falling around 30 points on Friday. Following the market opening Friday, the Dow traded down 0.04% to 34,931.47 while the... Via Benzinga Topics Stocks Exposures US Equities Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE November 16, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update November 07, 2023 From Vigil Neuroscience, Inc. Via GlobeNewswire Vigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuation October 18, 2023 JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenerative diseases. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 October 18, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 17, 2023 Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.